MARKET

AGEN

AGEN

Agenus
NASDAQ
3.390
-0.050
-1.45%
After Hours: 3.340 -0.05 -1.46% 17:15 03/27 EDT
OPEN
3.440
PREV CLOSE
3.440
HIGH
3.466
LOW
3.340
VOLUME
321.69K
TURNOVER
--
52 WEEK HIGH
7.34
52 WEEK LOW
1.380
MARKET CAP
130.17M
P/E (TTM)
-997.0588
1D
5D
1M
3M
1Y
5Y
1D
Agenus Cervical Cancer Trial Terminated: What RaPiDS Means for AGEN Investors
TipRanks · 2d ago
Agenus to host stakeholder webcast on BOT+BAL immunotherapy program; Q&A to follow live session
Reuters · 3d ago
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
Barchart · 3d ago
Agenus Securities Class Action Dismissed, Legal Risks Ease
TipRanks · 3d ago
Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend
Reuters · 3d ago
Weekly Report: what happened at AGEN last week (0316-0320)?
Weekly Report · 6d ago
Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer
Reuters · 03/19 21:22
Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026
Benzinga · 03/17 20:40
More
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Webull offers Agenus Inc stock information, including NASDAQ: AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.